Salarius Pharmaceuticals Inc (SLRX) has released an update.
Salarius Pharmaceuticals, Inc. has concluded a separation agreement with its CEO, David J. Arthur, effective February 20, 2024, transitioning him to a consultant role, wherein he’ll dedicate at least 10 hours a week and receive a monthly fee of $10,417 until February 2025. The company also amended its executive employment agreement to offer severance payment flexibility to its CFO, Mark J. Rosenblum. Additionally, it announced reduced compensation for non-employee directors to aid in cost-saving measures, aligning with its strategy to maximize shareholder value and support ongoing clinical trials.
For further insights into SLRX stock, check out TipRanks’ Stock Analysis page.